Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study ; volume:14 ; number:1 ; day:27 ; month:8 ; year:2024 ; pages:1-11 ; date:12.2024
Scientific reports ; 14, Heft 1 (27.8.2024), 1-11, 12.2024
- Urheber
-
Rizzo, Mimma
Soares, Andrey
Grande, Enrique
Bamias, Aristotelis
Kopp, Ray Manneh
Lenci, Edoardo
Buttner, Thomas
Salah, Samer
Grillone, Francesco
Carvalho, Icaro Thiago de
Tapia, Jose Carlos
Gucciardino, Calogero
Pinto, Alvaro
Mennitto, Alessia
Abahssain, Halima
Rescigno, Pasquale
Myint, Zin
Takeshita, Hideki
Spinelli, Gian Paolo
Popovic, Lazar
Vitale, Maria Giuseppa
Fiala, Ondrej
Giannatempo, Patrizia
Zakopoulou, Roubini
Carrozza, Francesco
Massari, Francesco
Monteiro, Fernando Sabino Marques
Pace, Maria Paola
Giannini, Massimo
Roviello, Giandomenico
Porta, Camillo
Battelli, Nicola
Kanesvaran, Ravindran
Santoni, Matteo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-70182-3
- URN
-
urn:nbn:de:101:1-2411130718483.615473676181
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rizzo, Mimma
- Soares, Andrey
- Grande, Enrique
- Bamias, Aristotelis
- Kopp, Ray Manneh
- Lenci, Edoardo
- Buttner, Thomas
- Salah, Samer
- Grillone, Francesco
- Carvalho, Icaro Thiago de
- Tapia, Jose Carlos
- Gucciardino, Calogero
- Pinto, Alvaro
- Mennitto, Alessia
- Abahssain, Halima
- Rescigno, Pasquale
- Myint, Zin
- Takeshita, Hideki
- Spinelli, Gian Paolo
- Popovic, Lazar
- Vitale, Maria Giuseppa
- Fiala, Ondrej
- Giannatempo, Patrizia
- Zakopoulou, Roubini
- Carrozza, Francesco
- Massari, Francesco
- Monteiro, Fernando Sabino Marques
- Pace, Maria Paola
- Giannini, Massimo
- Roviello, Giandomenico
- Porta, Camillo
- Battelli, Nicola
- Kanesvaran, Ravindran
- Santoni, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Pembrolizumab
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Pembrolizumab for all
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Pembrolizumab
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
Pembrolizumab for all
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Pembrolizumab
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan